Owing to the restricted oral bioavailability of antimigraine drugs Rizatriptan Benzoate (RNB), nasal delivery was employed in lieu of enhancing the bioavailability and brain targeting through utilizing spanlastics nanovascular. This work sought to formulate RNB as mucoadhesive spanlastics nanovesicles and assess the pharmacokinetic parameters and histopathological effects of the formulations on the nasal mucosa of rats. RNB was formulated as mucoadhesive spanlastics nanovesicles; the study comprised 68 Wistar rats, each weighing 200±35 g, divided into three groups (control, IN, and IV). RNB is quantified in rat plasma and brain using reverse-phase high-performance liquid chromatography (RP-HPLC). The pharmacokinetic studies on rats indicated that the brain Cmax of intranasal mucoadhesive RNB spanlastics was approximately two times greater than that of intravenous RNB – solution. No damage to the structure of the mucosal membrane was seen during the histological analysis. Consequently, the developed and optimized intranasal mucoadhesive RNB formula demonstrated outstanding potential for safe and effective administration of RNB.

Keywords: Rizatriptan benzoate. Mucoadhesive spanlastics, Nasal delivery ,Brain targeting